Education
About Us
Working with TipRanks
Follow Us
MDxHealth (MDXH)
NASDAQ:MDXH
Earnings Data
Report Date
May 14, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.14Last Year’s EPS
-0.19Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call portrayed a company in growth and transition: strong top-line and unit growth (notably a 62% unit increase and 128% rise in liquid volumes), successful integration steps with ExoDx and a clearer path to cross-selling and clinical validation, offset by near-term profitability pressure from integration costs, higher operating and financial expenses, and a modest downward adjustment to reported revenue. Management provided optimistic 2026 guidance (approx. 28% revenue growth and a target of 10% adjusted EBITDA exiting the year) and secured earnout amendment relief (~$20M), signaling confidence in returning to operating leverage despite short-term headwinds.Company Guidance
Strong Unit Growth and Mix Expansion
Q4 total billable volume ~38,000 tests (11,000 tissue; 27,000 liquid), representing unit growth of 62% year-over-year; liquid-based test volumes increased 128% YoY, driven by ExoDx and conversion of SelectMDx customers.
Quarterly Revenue and Gross Profit Growth
Q4 revenue rose 19% YoY to $29.5 million (from $24.7M); gross profit increased 20% to $18.7 million, with gross margin improving to 63.2% from 62.7% (+0.5 percentage points).
Full-Year Revenue and Modest Pre-Release Adjustment
Reported full-year revenue of $107.9 million (noted as $1 million below the pre-release estimate due to closing process rationalization after the ExoDx acquisition), with management stating the adjustment does not change 2026 guidance.
Successful Acquisition Integration and Customer Conversions
Initiated ExoDx integration in Q4 and transitioned all SelectMDx customers to ExoDx during the quarter, accelerating operating efficiencies and setting up cross-selling opportunities across the expanded menu.
2026 Growth Guidance and Profitability Target
Management guided 2026 revenue implying ~28% year-over-year growth (midpoint), expects >$20M contribution from ExoDx in 2026, and targets adjusted EBITDA of 10% of revenue as the company exits 2026.
Improved Operational Metrics and Clinical Program Progress
Operational improvements include best-in-class tissue turnaround time of five days or less; clinical milestones include completion of GPS PROMPT and commencement of GPS PROTECT (UK PROTECT trial enrollment >1,500), with potential to advance GPS in NCCN guidelines.
Capital Flexibility from Earnout Amendment
Amendment to Exact Sciences earnout lowers near-term payment by close to $20 million and defers remaining payments by an additional year, providing additional financial flexibility.
MDXH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
MDXH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 26, 2026 | $3.55 | $3.40 | -4.23% |
Nov 12, 2025 | $4.12 | $3.97 | -3.64% |
Aug 05, 2025 | $2.49 | $2.75 | +10.44% |
May 14, 2025 | $1.78 | $1.90 | +6.74% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does MDxHealth (MDXH) report earnings?
MDxHealth (MDXH) is schdueled to report earning on May 14, 2026, Before Open (Confirmed).
What is MDxHealth (MDXH) earnings time?
MDxHealth (MDXH) earnings time is at May 14, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MDXH EPS forecast?
MDXH EPS forecast for the fiscal quarter 2026 (Q1) is -0.14.